Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

60 Press Releases
DateTitleCompany
29 Mar 13 Millennium: The Takeda Oncology Company and the WIN Consortium Become Partners in the Fight Against Cancer Millennium: The Takeda Oncology Company,
Published by
Business Wire
04 Mar 13 Industry Leaders and Academic Researchers Come Together for Innovative Accelerating Cancer Cures Research Symposium Millennium: The Takeda Oncology Company,
Published by
Business Wire
23 Jan 13 Multiple Myeloma Research Foundation (MMRF) Names Millennium Collaborator of the Year Millennium: The Takeda Oncology Company,
Published by
Business Wire
11 Dec 12 Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis Millennium: The Takeda Oncology Company,
Published by
Business Wire
11 Dec 12 Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Hodgkin Lymphoma at ASH Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
10 Dec 12 Presentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
09 Dec 12 Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas Millennium: The Takeda Oncology Company,
Published by
Business Wire
09 Dec 12 Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 study Millennium: The Takeda Oncology Company,
Published by
Business Wire
06 Nov 12 VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Millennium Pipeline Agents to be Featured at American Society of Hematology Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
05 Nov 12 CORRECTING and REPLACING Millennium is #1 in Boston Globe Ranking of Top Largest Employer Millennium: The Takeda Oncology Company,
Published by
Business Wire
05 Nov 12 Millennium is #1 in Boston Globe Ranking of Best Large Employers Millennium: The Takeda Oncology Company,
Published by
Business Wire
01 Nov 12 Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma Millennium: The Takeda Oncology Company and Seattle Genetics Inc.,
Published by
Business Wire
31 Oct 12 Takeda and Millennium Announce European Conditional Marketing Authorisation for ADCETRIS® (Brentuximab Vedotin) Millennium: The Takeda Oncology Company,
Published by
Business Wire
31 Oct 12 Millennium and Takeda Announce European Conditional Marketing Authorization for ADCETRIS® (Brentuximab Vedotin) Millennium: The Takeda Oncology Company,
Published by
Business Wire
19 Oct 12 Millennium Initiates Global TOURMALINE-AL1 Pivotal Phase 3 Trial of MLN9708 In Patients with Relapsed or Refractory Primary (AL) Amyloidosis Millennium: The Takeda Oncology Company,
Published by
Business Wire
01 Oct 12 Millennium and Seattle Genetics Highlight Data from ADCETRIS® (Brentuximab Vedotin) Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
21 Sep 12 Millennium Ranked In Top 10 Biotech / Biopharmaceutical Companies For 5th Consecutive Year Millennium: The Takeda Oncology Company,
Published by
Business Wire
20 Jul 12 Millennium and Takeda Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS® (brentuximab vedotin) in Europe Millennium: The Takeda Oncology Company,
Published by
Business Wire
28 Jun 12 Millennium Initiates TOURMALINE-MM1 Pivotal Phase 3 Trial of MLN9708 in Patients With Relapsed and/or Refractory Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
14 Jun 12 Millennium Highlights Updated Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
03 Jun 12 ASCO Presentations Highlight Preliminary Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Clinical Trials in Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
23 May 12 Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
07 May 12 Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRISÔäó in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma Millennium: The Takeda Oncology Company and Seattle Genetics Inc.,
Published by
Business Wire
06 Apr 12 Presage Biosciences and Millennium Enter Into Cancer Research Agreement Millennium: The Takeda Oncology Company,
Published by
Business Wire
24 Jan 12 FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications Millennium: The Takeda Oncology Company,
Published by
Business Wire
21 Dec 11 Takeda to Acquire Intellikine, Adding Two Novel Programs to its Oncology Pipeline Millennium: The Takeda Oncology Company,
Published by
Business Wire
20 Dec 11 Presentations Highlight Results of Clinical Data for MLN8237 and VELCADE® in the Treatment of Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
13 Dec 11 Presentations Highlight Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Early Stage Clinical Trials in Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
13 Dec 11 Overall Survival Benefit with VELCADE® Based Therapy in Previously Untreated Multiple Myeloma Patients Maintained After Five Year Follow-Up Millennium: The Takeda Oncology Company,
Published by
Business Wire
08 Nov 11 More than Thirty Abstracts on VELCADE® and Leading Millennium Pipeline Compounds to be Presented in Oral Sessions at 53rd American Society of Hematology Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
Advertising